ReviewJournal of endocrinological investigation2026
Heme oxygenase-1 in thyroid cancer: a context-dependent regulator.
Review in Journal of endocrinological investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeHeme oxygenase-1 (HO-1) catalyzes the rate-limiting step of heme degradation and has traditionally been regarded as a cytoprotective, antioxidant enzyme. However, HO-1 also influences tumour behaviour through activities independent of its catalytic function. This review aims to integrate current evidence on HO-1 regulation and function in thyroid cancer and to examine how its context-dependent actions may influence tumour biology and therapeutic response.
methodsWe review available preclinical and clinical evidence on HO-1 in thyroid cancer, with particular emphasis on oxidative stress, metabolic reprogramming, tumour progression, subcellular localization, and the potential therapeutic implications of HO-1 modulation.
resultsCurrent evidence links HO-1 to proliferation, redox homeostasis, and metabolic flexibility in thyroid cancer. Importantly, its effects are not uniform but appear to depend on tumour subtype, cellular context, structural state, and intracellular compartment. In particular, nuclear HO-1 may mediate non-enzymatic functions associated with more aggressive and treatment-refractory phenotypes. Although modulation of HO-1 has potential therapeutic relevance, supporting evidence remains predominantly preclinical.
conclusionHO-1 should not be considered solely as an antioxidant enzyme in thyroid cancer, but rather as a context-dependent regulator whose functional output is shaped by tumour context and subcellular localization. Further clinical validation is required to establish its prognostic and therapeutic relevance.
Indexed as
Identifiers
42606811What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.